Vertex’s Kalydeco May Face Added Cost Assessments In Germany
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex Pharmaceutical’s orphan drug for cystic fibrosis may face an additional reimbursement evaluation in Germany after IQWiG says it may breach the €50 million per year cost threshold.